1
|
Al-Saeedi F, Rajendran P, Tipre D, Aladwani H, Alenezi S, Alqabandi M, Alkhamis A, Redha A, Mohammad A, Ahmad F, Abdulnabi Y, Alfadhly A, Alrasheedi D. The effect of COVID-19 on nuclear medicine and radiopharmacy activities: A global survey. Sci Rep 2023; 13:10489. [PMID: 37380735 PMCID: PMC10307835 DOI: 10.1038/s41598-023-36925-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2022] [Accepted: 06/12/2023] [Indexed: 06/30/2023] Open
Abstract
Globally, COVID-19 affected radiopharmaceutical laboratories. This study sought to determine the economic, service, and research impacts of COVID-19 on radiopharmacy. This online survey was conducted with the participation of employees from nuclear medicine and radiopharmaceutical companies. The socioeconomic status of the individuals was collected. The study was participated by 145 medical professionals from 25 different countries. From this work, it is evident that 2-deoxy-2-[18F]fluoro-D-glucose (2-[18F]FDG), and 99mTc-labeled macro aggregated albumin 99mTc-MAA were necessary radiopharmaceuticals used by 57% (83/145and 34% (49/145;) respondents, respectively for determining how COVID infections affect a patient's body. The normal scheduling procedure for the radiopharmacy laboratory was reduced by more than half (65%; 94/145). In COVID-19, 70% (102/145) of respondents followed the regulations established by the local departments. Throughout the pandemic, there was a 97% (141/145) decrease in all staffing recruitment efforts. The field of nuclear medicine research, as well as the radiopharmaceutical industry, were both adversely affected by COVID-19.
Collapse
Affiliation(s)
- Fatma Al-Saeedi
- The Department of Nuclear Medicine, College of Medicine, Kuwait University, P.O. box: 24923, 13110, Safat, Kuwait.
| | - Peramaiyan Rajendran
- Department of Biological Sciences, College of Science, King Faisal University, AlAhsa, Saudi Arabia
- Department of Biochemistry, Saveetha Dental College & Hospitals, Saveetha Institute of Medical and Technical Sciences, Chennai, 600 077, Tamil Nadu, India
| | - Dnyanesh Tipre
- Translational Biomedical Imaging Laboratory, Department of Radiology, Children's Hospital Los Angeles, Los Angeles, California, USA
| | - Hassan Aladwani
- College of Medicine, Kuwait University, P.O. box: 24923, 13110, Safat, Kuwait
| | - Salem Alenezi
- College of Medicine, Kuwait University, P.O. box: 24923, 13110, Safat, Kuwait
| | - Maryam Alqabandi
- The Department of Nuclear Medicine, College of Medicine, Kuwait University, P.O. box: 24923, 13110, Safat, Kuwait
| | - Abdullah Alkhamis
- College of Medicine, Kuwait University, P.O. box: 24923, 13110, Safat, Kuwait
| | - Abdulmohsen Redha
- College of Medicine, Kuwait University, P.O. box: 24923, 13110, Safat, Kuwait
| | - Ahmed Mohammad
- College of Medicine, Kuwait University, P.O. box: 24923, 13110, Safat, Kuwait
| | - Fahad Ahmad
- College of Medicine, Kuwait University, P.O. box: 24923, 13110, Safat, Kuwait
| | - Yaaqoup Abdulnabi
- College of Medicine, Kuwait University, P.O. box: 24923, 13110, Safat, Kuwait
| | - Altaf Alfadhly
- College of Medicine, Kuwait University, P.O. box: 24923, 13110, Safat, Kuwait
| | - Danah Alrasheedi
- College of Medicine, Kuwait University, P.O. box: 24923, 13110, Safat, Kuwait
| |
Collapse
|
2
|
Shaffaf T, Ghafar-Zadeh E. COVID-19 Diagnostic Strategies Part II: Protein-Based Technologies. Bioengineering (Basel) 2021; 8:54. [PMID: 33925032 PMCID: PMC8145709 DOI: 10.3390/bioengineering8050054] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2021] [Revised: 04/08/2021] [Accepted: 04/22/2021] [Indexed: 02/07/2023] Open
Abstract
After the initiation of the current outbreak, humans' lives have been profoundly impacted by COVID-19. During the first months, no rapid and reliable detecting tool was readily available to sufficiently respond to the requirement of massive testing. In this situation, when the development of an effective vaccine requires at least a few months, it is crucial to be prepared by developing and commercializing affordable, accurate, rapid and adaptable biosensors not only to fight Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) but also to be armed to avoid the pandemic in the earliest stages in the future. The COVID-19 diagnostic tools are categorized into two main groups of Nucleic Acid (NA)-based and protein-based tests. To date, nucleic acid-based detection has been announced as the gold-standard strategy for coronavirus detection; however, protein-based tests are promising alternatives for rapid and large-scale screening of susceptible groups. In this review, we discuss the current protein-based biosensing tools, the research advances and the potential protein-detecting strategies for COVID-19 detection. This narrative review aims to highlight the importance of the diagnostic tests, encourage the academic research groups and the companies to eliminate the shortcomings of the current techniques and step forward to mass-producing reliable point-of-care (POC) and point-of-need (PON) adaptable diagnostic tools for large-scale screening in the future outbreaks.
Collapse
Affiliation(s)
- Tina Shaffaf
- Biologically Inspired Sensors and Actuators Laboratory (BioSA), York University, Toronto, ON M3J1P3, Canada;
- Department of Biology, Faculty of Science, York University, Toronto, ON M3J1P3, Canada
| | - Ebrahim Ghafar-Zadeh
- Biologically Inspired Sensors and Actuators Laboratory (BioSA), York University, Toronto, ON M3J1P3, Canada;
- Department of Biology, Faculty of Science, York University, Toronto, ON M3J1P3, Canada
- Department of Electrical Engineering and Computer Science, Lassonde School of Engineering, York University, Toronto, ON M3J1P3, Canada
| |
Collapse
|
3
|
Shaffaf T, Ghafar-Zadeh E. COVID-19 Diagnostic Strategies. Part I: Nucleic Acid-Based Technologies. Bioengineering (Basel) 2021; 8:49. [PMID: 33920513 PMCID: PMC8072613 DOI: 10.3390/bioengineering8040049] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2021] [Revised: 04/14/2021] [Accepted: 04/15/2021] [Indexed: 12/11/2022] Open
Abstract
The novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused respiratory infection, resulting in more than two million deaths globally and hospitalizing thousands of people by March 2021. A considerable percentage of the SARS-CoV-2 positive patients are asymptomatic or pre-symptomatic carriers, facilitating the viral spread in the community by their social activities. Hence, it is critical to have access to commercialized diagnostic tests to detect the infection in the earliest stages, monitor the disease, and follow up the patients. Various technologies have been proposed to develop more promising assays and move toward the mass production of fast, reliable, cost-effective, and portable PoC diagnostic tests for COVID-19 detection. Not only COVID-19 but also many other pathogens will be able to spread and attach to human bodies in the future. These technologies enable the fast identification of high-risk individuals during future hazards to support the public in such outbreaks. This paper provides a comprehensive review of current technologies, the progress in the development of molecular diagnostic tests, and the potential strategies to facilitate innovative developments in unprecedented pandemics.
Collapse
Affiliation(s)
- Tina Shaffaf
- Biologically Inspired Sensors and Actuators Laboratory (BioSA), York University, Toronto, ON M3J1P3, Canada;
- Faculty of Science, Department of Biology, York University, Toronto, ON M3J1P3, Canada
| | - Ebrahim Ghafar-Zadeh
- Biologically Inspired Sensors and Actuators Laboratory (BioSA), York University, Toronto, ON M3J1P3, Canada;
- Faculty of Science, Department of Biology, York University, Toronto, ON M3J1P3, Canada
- Lassonde School of Engineering, Department of Electrical Engineering and Computer Science, York University, Toronto, ON M3J1P3, Canada
| |
Collapse
|
4
|
Recent Developments in SARS-CoV-2 Neutralizing Antibody Detection Methods. Curr Med Sci 2021; 41:1052-1064. [PMID: 34935114 PMCID: PMC8692081 DOI: 10.1007/s11596-021-2470-7] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Accepted: 10/20/2021] [Indexed: 12/14/2022]
Abstract
The ongoing Coronavirus disease 19 pandemic has likely changed the world in ways not seen in the past. Neutralizing antibody (NAb) assays play an important role in the management of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak. Using these tools, we can assess the presence and duration of antibody-mediated protection in naturally infected individuals, screen convalescent plasma preparations for donation, test the efficacy of immunotherapy, and analyze NAb titers and persistence after vaccination to predict vaccine-induced protective effects. This review briefly summarizes the various methods used for the detection of SARS-CoV-2 NAbs and compares their advantages and disadvantages to facilitate their development and clinical application.
Collapse
|
5
|
Scalable COVID-19 Detection Enabled by Lab-on-Chip Biosensors. Cell Mol Bioeng 2020; 13:313-329. [PMID: 32837587 PMCID: PMC7416807 DOI: 10.1007/s12195-020-00642-z] [Citation(s) in RCA: 53] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2020] [Accepted: 07/27/2020] [Indexed: 12/18/2022] Open
Abstract
Introduction The emergence of a novel coronavirus, SARS-CoV-2, has highlighted the need for rapid, accurate, and point-of-care diagnostic testing. As of now, there is not enough testing capacity in the world to meet the stated testing targets, which are expected to skyrocket globally for broader testing during reopening Aim This review focuses on the development of lab-on-chip biosensing platforms for diagnosis of COVID-19 infection. Results We discuss advantages of utilizing lab-on-chip technologies in response to the current global pandemic, including their potential for low-cost, rapid sample-to-answer processing times, and ease of integration into a range of healthcare settings. We then highlight the development of magnetic, colorimetric, plasmonic, electrical, and lateral flow-based lab-on-chip technologies for the detection of SARS-CoV-2, in addition to other viruses. We focus on rapid, point-of-care technologies that can be deployed at scale, as such devices could be promising alternatives to the current gold standard of reverse transcription-polymerase chain reaction (RT-PCR) diagnostic testing. Conclusion This review is intended to provide an overview of the current state-of-the-field and serve as a resource for innovative development of new lab-on-chip assays for COVID-19 detection.
Collapse
|